NASDAQ · Shell Companies · USD

Drugs Made In America Acquisition Corp. (DMAAU) Stock Analysis

Drugs Made In America Acquisition Corp. (DMAAU) is a Shell Companies stock listed on NASDAQ and quoted in US Dollar.

DMAAU

$10.79

$0.00 (0.00%)

Sep 4, 2026 · Market close

This is a derivative instrument — a unit issued alongside Drugs Made In America Acquisition Corp. (DMAA) common stock.

Issuer fundamentals are shown on the issuer page, not here.

View DMAA →

Price History

Hover for the daily close. The dotted line marks the period open.

DMAAU Key Statistics

As of Sep 4, 2026

Trading

Open: $10.79
Previous Close: $10.79
52-Week Range: 10.30–12.50

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

DMAAU Stock Return by Calendar Year

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

Year	Return
2026 (partial year)	+2.86%
2025	+4.90%

As of September 4, 2026.

Related Shell Companies Stocks

CCXI

Churchill Capital Corp XI

$746.38M

CCCX

Churchill Capital Corp X

$711.00M

DMII

Drugs Made In America Acquisition II Corp.

$647.83M

BCSS

Bain Capital GSS Investment Corp.

$602.40M

EVAC

EQV Ventures Acquisition Corp. II

$602.01M

CXII

Churchill Capital Corp XII

$594.94M

View all Shell Companies stocks →

Popular Financial Services Stocks

BRK-B

Berkshire Hathaway Inc.

$1.08T

JPM

JPMorgan Chase & Co.

$953.33B

Visa Inc.

$700.27B

Mastercard Incorporated

$507.39B

BAC

Bank of America Corporation

$438.31B

View all Financial Services stocks →

About Drugs Made In America Acquisition Corp.

Drugs Made In America Acquisition Corp. does not have significant operations. It intends to effect a merger, share exchange, asset acquisition, share purchase, recapitalization, reorganization, or other similar business combinations with one or more businesses. Drugs Made In America Acquisition Corp. was incorporated in 2024 and is based in New York, New York.